THE DEFINITIVE PLATFORM FOR DRUGGING CONDENSATES
Condensates play a critical role in a number of important and historically intractable targets for disease
Starting with the study of stress granules and their role in ALS, the Hyman Lab began to connect biomolecular condensates to disease. Dewpoint now believes that a vast range of diseases have pathways that are regulated by condensates or arise from the dysfunction of condensates, in areas spanning cancer, neurodegeneration, cardiovascular disease, and metabolic disease.
In addition, biomolecular condensates offer a new approach to “undruggable” target classes like transcription factors and RNA.
Research in Biomolecular Condensates & Disease
Dewpoint is building proprietary tools for purposefully exploiting condensates to treat the most important diseases that face mankind. If you would like to learn more about our platform please contact us.